Mizuho Forecasts Strong Price Appreciation for DENTSPLY SIRONA (NASDAQ:XRAY) Stock

DENTSPLY SIRONA (NASDAQ:XRAY) had its price objective hoisted by stock analysts at Mizuho from $14.00 to $16.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “neutral” rating on the medical instruments supplier’s stock. Mizuho’s target price would suggest a potential upside of 8.99% from the stock’s current price.

A number of other equities research analysts also recently weighed in on XRAY. UBS Group lowered their price target on DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Robert W. Baird raised their price objective on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday. Zacks Research lowered DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a research note on Monday, November 10th. Wells Fargo & Company lifted their price target on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday. Finally, Stifel Nicolaus set a $13.00 price objective on shares of DENTSPLY SIRONA in a research note on Thursday, November 6th. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $14.42.

DENTSPLY SIRONA Price Performance

NASDAQ:XRAY opened at $14.68 on Monday. The firm has a market capitalization of $2.93 billion, a price-to-earnings ratio of -4.89, a P/E/G ratio of 1.19 and a beta of 0.97. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. The stock has a fifty day moving average of $12.42 and a 200 day moving average of $12.47. DENTSPLY SIRONA has a 52-week low of $9.85 and a 52-week high of $17.34.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The business had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business’s revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, research analysts expect that DENTSPLY SIRONA will post 1.84 EPS for the current fiscal year.

Insider Buying and Selling at DENTSPLY SIRONA

In related news, Director Gregory T. Lucier sold 82,200 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $11.14, for a total value of $915,708.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.52% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

Large investors have recently made changes to their positions in the business. AQR Capital Management LLC lifted its stake in DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after acquiring an additional 6,970,086 shares during the period. Armistice Capital LLC raised its holdings in DENTSPLY SIRONA by 1,044.0% in the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after purchasing an additional 5,234,587 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of DENTSPLY SIRONA by 662.0% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier’s stock worth $58,480,000 after purchasing an additional 4,003,606 shares during the period. Norges Bank bought a new stake in shares of DENTSPLY SIRONA during the 2nd quarter valued at about $39,700,000. Finally, Goldman Sachs Group Inc. increased its position in shares of DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after buying an additional 2,172,343 shares during the period. 95.70% of the stock is currently owned by institutional investors.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.